MARKET NEWS

Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility
Multiple Headlands Research Sites Selected for AstraZeneca’s Phase 3 COVID-19 Vaccine Trial
FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19
Eyenovia & Arctic Vision Announce Exclusive Collaboration & License Agreement
Immutep Granted US Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Clearside Biomedical Announces US FDA Acceptance of IND Application 
Arcturus Therapeutics Announces Dosing of its COVID-19 Vaccine Candidate in Phase 1/2 Study

  FEATURED EDITORIAL

  COMPANY PROFILE

Bioiberica is a global Life Science company specialised in the identification, extraction and development of biomolecules of high biological and therapeutic value for the pharmaceutical and nutraceutical industries. Over the last 40 years, this specialisation has positioned Bioiberica as the leading Heparin API manufacturer and a world reference in the research, production and sale of animal-derived APIs and ingredients. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Scioto Biosciences Receives .5 Million Series B Investment From Genome & Company

Scioto Biosciences Receives $26.5 Million Series B Investment From Genome & Company

Scioto Biosciences recently announced the closing of a strategic investment of up to $26.5 million from Genome & Company and other investors to join in an upcoming tranche….

Protalix BioTherapeutics & Chiesi Global Rare Diseases Announce US FDA Acceptance of Biologics License Application 

Protalix BioTherapeutics & Chiesi Global Rare Diseases Announce US FDA Acceptance of Biologics License Application 

Protalix BioTherapeutics, Inc. together with its development and commercialization partner Chiesi Global Rare Diseases recently announced the US FDA has accepted the Biologics License Application (BLA) and granted….

MyoKardia & LianBio Form Strategic Development & Commercialization Partnership

MyoKardia & LianBio Form Strategic Development & Commercialization Partnership

MyoKardia, Inc. and LianBio recently announced they have entered into a strategic collaboration to develop and commercialize….

GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050

GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050

GigaGen presents a novel technology for producing a new class of drug, which it calls recombinant hyperimmunes…..

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 26 – Transdermal/Topical Delivery
September 2 – Drug Delivery